On Monday, Capricor Therapeutics Inc (NASDAQ: CAPR) was -5.97% drop from the session before settling in for the closing price of $14.23. A 52-week range for CAPR has been $3.52 – $23.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 85.83%. When this article was written, the company’s average yearly earnings per share was at 96.52%. With a float of $40.15 million, this company’s outstanding shares have now reached $45.68 million.
Considering the fact that the conglomerate employs 160 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 100.0%, operating margin of -329.9%, and the pretax margin is -317.13%.
Capricor Therapeutics Inc (CAPR) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Capricor Therapeutics Inc stocks. The insider ownership of Capricor Therapeutics Inc is 12.16%, while institutional ownership is 40.49%. The most recent insider transaction that took place on Sep 20 ’24, was worth 14,999,998. In this transaction 10% Owner of this company bought 2,798,507 shares at a rate of $5.36, taking the stock ownership to the 7,090,351 shares.
Capricor Therapeutics Inc (CAPR) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 96.52% per share during the next fiscal year.
Capricor Therapeutics Inc (NASDAQ: CAPR) Trading Performance Indicators
You can see what Capricor Therapeutics Inc (CAPR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 35.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.42, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -0.53 in one year’s time.
Technical Analysis of Capricor Therapeutics Inc (CAPR)
Compared to the last year’s volume of 1.68 million, its volume of 2.39 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 87.08%. Additionally, its Average True Range was 1.18.
During the past 100 days, Capricor Therapeutics Inc’s (CAPR) raw stochastic average was set at 69.74%, which indicates a significant decrease from 70.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.15% in the past 14 days, which was lower than the 117.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.40, while its 200-day Moving Average is $13.07. Nevertheless, the first resistance level for the watch stands at $14.51 in the near term. At $15.64, the stock is likely to face the second major resistance level. The third major resistance level sits at $16.28. If the price goes on to break the first support level at $12.74, it is likely to go to the next support level at $12.10. Now, if the price goes above the second support level, the third support stands at $10.97.
Capricor Therapeutics Inc (NASDAQ: CAPR) Key Stats
There are 45,677K outstanding shares of the company, which has a market capitalization of 611.57 million. As of now, sales total 22,270 K while income totals -40,470 K. Its latest quarter income was 11,130 K while its last quarter net income were -7,120 K.
